Dr Michelle Teng

Etcembly’s CEO and co-founder Michelle has a PhD in Immunogenetics from the University of Cambridge and has won several awards for her work. She transitioned into TCR biologics in 2012 when she joined Immunocore, and has >20 years’ experience in projects ranging from lead discovery to translational medicine. Michelle co-founded Etcembly in 2020 to realise the potential of using machine learning to design biologics for disease.